PSYCHEDELIC ALPHA

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond.

An Introduction to the Psychedelic Renaissance

40% of American adults report struggling with mental health or substance abuse disorders. Psychedelics may provide solutions to the global mental health and wellbeing crisis.

After decades of repression, psychedelic research is thriving.

Promising research has already resulted in FDA Breakthrough Therapy designations for psilocybin-assisted therapies aimed at treating depression, and MDMA-assisted psychotherapy for PTSD. Research on other ‘psychedelics’, including MDMA and LSD, is picking up pace with research centres at prestigious institutions—including Johns Hopkins and Imperial College London—driving a new wave of psychedelic research.

Decriminalisation and legalisation campaigns are succeeding.

In 2020 the U.S. state of Oregon voted to decriminalise psychedelics and legalise Psilocybin Therapy. Washington, D.C., home of the White House, also decriminalised psychedelics, with many other states and localities poised to follow suit. Canada’s Health Minister has granted exemptions to allow access to psilocybin-assisted psychotherapy, setting precedent for future efforts to expand access.

Significant clinical trial milestones on the horizon.

In a Phase 3 MDMA-assisted therapy for PTSD trial that published last year, 88% of participants responded to the treatment. The trial’s sponsor, MAPS, expects to seek FDA approval in or around 2024. Multiple trials of psilocybin for depression are in Phase 2 or entering Phase 3, and are indicating preliminary safety and efficacy.

Psychedelics have the potential to address depression anxiety addiction PTSD chronic pain

Welcome to the Psychedelic Renaissance.

The Psychedelic Renaissance in Context

Today’s psychedelic renaissance benefits from a rich legacy of psychedelic research and usage dating back to pre-historic times.

The extensive psychedelic research and experimentation of the 1950s and ’60s represents a significant endowment, with today’s researchers taking up the torch.

1943

Albert Hofmann intentionally ingests LSD, experiencing the effects while cycling home. “Bicycle Day” is coined.

mid 1960s – 1971

Psychedelics criminalised, with Nixon declaring a War on Drugs in 1971 and a UN Convention following suit.

~10,000 BCE

Psychedelic iconography, such as mushrooms, appear in etched murals dating 10,000 BCE.

1950s and ’60s

Fertile decades for psychedelics research and experimentation, particularly in the U.S.

21st Century

Psychedelic renaissance emerges, with a return to human studies of psychedelics and decriminalisation campaigns.

Our Latest Analysis

Psychedelic Bulletin #130: Australia to Reschedule MDMA and Psilocybin; Small Pharma Reports Positive DMT Data; Journey Clinical Closes $8.5m Series A

A look at Australia’s rescheduling of MDMA and Psilocybin; Small Pharma’s Phase 2a DMT results; Journey Clinical’s Series A round; and lots more…

Psychedelic Bulletin #129: New Year, New Psychedelic Bills; WHO Dubs 5-MeO-DMT ‘Mebufotenin’

This week: we briefly look at four new psychedelic policy reform bills from across the U.S.; the World Health Organisation gives 5-MeO-DMT a generic name; and more…

Psychedelic Bulletin #128: atai Results Disappoint; MAPS Confirmatory Phase 3 Study “Successful”; New York Bill Would Legalize Psychedelics; Oregon Begins Accepting Licence Applications

This week: PCN-101 results disappoint; MDMA for PTSD appears to have succeeded in second Phase 3 study; a Bill introduced in New York would legalize a number of psychedelics; Oregon begins accepting applications for psilocybin-related licences; and much more…

Receive Our Updates

Join our Newsletter

Psychedelic insights, commentary and analysis delivered to your inbox, including our weekly Bulletin.

Follow Us on Twitter

Join us on Twitter where we share the latest news and analysis, covering the entire psychedelic space.

Axios Logo
Business Insider logo grey
New York Times
Mother Jones Logo
Rolling Stone Logo
Finimize logo grey
Vice Logo